Clinical trial
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
NCT07669220 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 1, 2026
- Completion date
- January 1, 2028
- Enrollment
- 76 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
folfox, high-risk locally advanced, immunotherapy, rectal adenocarcinoma, short-course radiotherapy (scrt)